There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments.
Establishment Labs Holdings (ESTA)
In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Establishment Labs Holdings, with a price target of $53.00. The company’s shares closed last Tuesday at $50.45.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
Establishment Labs Holdings has an analyst consensus of Strong Buy, with a price target consensus of $56.00, representing a 17.5% upside. In a report issued on April 1, Mizuho Securities also reiterated a Buy rating on the stock with a $65.00 price target.
See today’s best-performing stocks on TipRanks >>
Gritstone Oncology (GRTS)
BTIG analyst Kaveri Pohlman maintained a Buy rating on Gritstone Oncology yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $1.20, close to its 52-week low of $1.14.
According to TipRanks.com, Pohlman is a 3-star analyst with an average return of
Gritstone Oncology has an analyst consensus of Strong Buy, with a price target consensus of $5.60, representing a 330.8% upside. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ESTA:
- Establishment Labs price target raised to $65 from $50 at Mizuho
- Establishment Labs price target raised to $60 from $50 at TD Cowen
- New Regulation Risk for Establishment Labs Holdings – What’s the Latest?
- Establishment Labs price target raised to $49 from $32 at Citi
- Establishment Labs price target raised to $53 from $45 at BTIG
